MAT2A and hepatocellular carcinoma: It has been demonstrated that treatment with an adenosine aspartyl-derivative (IFC305) increases the MAT1A and decreases MAT2A levels, restoring transmethylation activities and facilitating chemoprotective effects against HCC [136].